The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase (Ph) I/II study of pembrolizumab (P) with gemcitabine (G) in patients (pts) with previously-treated advanced (Adv) non-small cell lung cancer (NSCLC).
 
Rachel E. Sanborn
Honoraria - AstraZeneca
Consulting or Advisory Role - Abbvie; Amgen; ARIAD; AstraZeneca; Celldex; Genentech/Roche; Peregrine Pharmaceuticals; Roche/Genentech; Seagen; Takeda
Research Funding - Bristol-Myers Squibb (Inst); MedImmune (Inst); Merck
Travel, Accommodations, Expenses - Five Prime Therapeutics; Janssen Oncology
 
Regan M. Duffy
No Relationships to Disclose
 
Brenda K Fisher
Consulting or Advisory Role - AstraZeneca
 
Kelly Shea Perlewitz
No Relationships to Disclose
 
Herschel D. Wallen
No Relationships to Disclose
 
Rui Li
No Relationships to Disclose
 
William L Redmond
Consulting or Advisory Role - Alligator Bioscience; Nektar; Vesselon
Research Funding - Aeglea Biotherapeutics; Bristol-Myers Squibb; Galectin Therapeutics; MedImmune; Merck; Nektar; Tesaro; Veana Therapeutics
Patents, Royalties, Other Intellectual Property - Galectin Therapeutics; MedImmune
 
Yoshinobu Koguchi
Honoraria - Curiox BioSystems; Shimadzu
Consulting or Advisory Role - Curiox BioSystems
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Nektar (Inst); Shimadzu (Inst); Tesaro (Inst)
Patents, Royalties, Other Intellectual Property - BACTERIAL VACCINES DEFICIENT IN THE 2-C-METHYL-D-ERYTHRITOL-4-PHOSPHATE PATHWAY AND METHODS OF PREPARATION AND USE THEREOF Publication number: 20170216420; CXCL11 AND SMICA AS PREDICTIVE BIOMARKERS FOR EFFICACY OF ANTI-CTLA4 IMMUNOTHERAPY Publication number: 20180246113 https://patents.justia.com/inventor/yoshinobu-koguchi
Travel, Accommodations, Expenses - Shimadzu
 
Bernard A. Fox
Employment - UbiVac; UbiVac (I)
Leadership - UbiVac
Stock and Other Ownership Interests - PrimeVax; UbiVac
Honoraria - Janssen Biotech; Nodality
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Celldex; Definiens; Macrogenics; MedImmune; OncoSec
Research Funding - Akoya Biosciences; Bristol-Myers Squibb; DEfiniens; Janssen Biotech; Macrogenics; MedImmune (Inst); Merck; NanoString Technologies; OncoSec; Perkin Elmer; Shimadzu; Viralytics
Patents, Royalties, Other Intellectual Property - Patent around the DPV-001 cancer vaccine. This patent is owned by the Providence Health System and licensed to UbiVac
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Definiens; Definiens; NanoString Technologies